Sei Investments Co. Makes New $69,000 Investment in ProKidney Corp. (NASDAQ:PROK)

Sei Investments Co. acquired a new stake in ProKidney Corp. (NASDAQ:PROK) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 41,062 shares of the company’s stock, valued at approximately $69,000.

Other institutional investors have also recently modified their holdings of the company. Geode Capital Management LLC lifted its stake in ProKidney by 102.0% during the third quarter. Geode Capital Management LLC now owns 2,203,934 shares of the company’s stock worth $4,232,000 after purchasing an additional 1,112,933 shares during the last quarter. State Street Corp raised its holdings in shares of ProKidney by 16.2% during the 3rd quarter. State Street Corp now owns 1,428,318 shares of the company’s stock worth $2,742,000 after buying an additional 198,836 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of ProKidney by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 759,787 shares of the company’s stock worth $1,284,000 after buying an additional 10,069 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in ProKidney in the fourth quarter valued at about $961,000. Finally, Bank of New York Mellon Corp grew its position in ProKidney by 20.6% in the fourth quarter. Bank of New York Mellon Corp now owns 229,770 shares of the company’s stock valued at $388,000 after acquiring an additional 39,275 shares during the last quarter. 51.59% of the stock is currently owned by institutional investors.

ProKidney Trading Up 19.2 %

PROK stock opened at $0.73 on Friday. The firm has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.54. ProKidney Corp. has a 12 month low of $0.46 and a 12 month high of $4.44. The stock has a market capitalization of $214.05 million, a P/E ratio of -1.33 and a beta of 1.52.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings data on Monday, March 17th. The company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.03). The company had revenue of $0.08 million for the quarter. As a group, equities analysts predict that ProKidney Corp. will post -0.57 EPS for the current fiscal year.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.